Enanta Pharmaceuticals, Inc. (ENTA) |
| 11.46 0.16 (1.42%) 10-09 16:00 |
| Open: | 11.4 |
| High: | 11.82 |
| Low: | 11.16 |
| Volume: | 360,909 |
| Market Cap: | 245(M) |
| PE Ratio: | -2.65 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 17.92 |
| Resistance 1: | 15.34 |
| Pivot price: | 9.97 |
| Support 1: | 10.22 |
| Support 2: | 7.05 |
| 52w High: | 15.34 |
| 52w Low: | 4.09 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Financials
| EPS | -4.320 |
| Book Value | 3.710 |
| PEG Ratio | 0.00 |
| Gross Profit | 2.325 |
| Profit Margin (%) | -141.98 |
| Operating Margin (%) | -103.16 |
| Return on Assets (ttm) | -17.3 |
| Return on Equity (ttm) | -80.6 |
Company news
Fri, 03 Oct 2025
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward - simplywall.st
Fri, 03 Oct 2025
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward - Sahm
Thu, 02 Oct 2025
$74.75M Raised: Enanta Closes Upsized 7,475,000-Share Offering to Fund Clinical Trials - Stock Titan
Wed, 01 Oct 2025
Jefferies Upgrades Enanta Pharma (ENTA) Rating to 'Buy' with Rai - GuruFocus
Wed, 01 Oct 2025
Enanta pharmaceuticals prices $65M common stock offering - MSN
Tue, 30 Sep 2025
Enanta Pharmaceuticals falls on public offering of common stock - MSN
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
